Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a 500‑patient phase 3 trial for previously treated metastatic pancreatic cancer (RASolute 302; NEJM, May 31, 2026). Developed from an academic spinout and advanced through acquisition and optimization, the drug uses a partner‑protein strategy to target previously “undruggable” RAS. Results show strong efficacy, high rates of adverse events but fewer discontinuations than chemo, and potential expansion into other RAS‑driven cancers — a possible inflection point for oncology drug development.